Metastatic renal cell carcinoma: Current standards of care

Clinical Journal of Oncology Nursing

Volumn 13, Issue SUPPL. 6, 2009, Pages 8-12

  Thompson, John A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; EVEROLIMUS; INDOLE DERIVATIVE; INTERLEUKIN 2; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; ONCOLOGY NURSING; REVIEW;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INDOLES; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; ONCOLOGIC NURSING; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SIROLIMUS;

EID: 77949523132     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.S2.8-12     Document Type: Article

References (29)

1. Amato, R.J. (2005). Renal cell carcinoma: Review of novel singleagent therapeutics and combination regimens. Annals of Oncology, 16(1), 7-15.
2. Canda, A.E., & Kirkali, Z. (2006). Management of renal cell carcinoma and targeted therapy. Urology Journal, 3(1), 1-14.
3. ® [Prescribing information]. Emeryville, CA: Author.
4. Cohen, H.T., & McGovern, F.J. (2005). Renal cell carcinoma. New England Journal of Medicine, 355(55), 2477-2490.
5. Drucker, B.J. (2005). Renal cell carcinoma: Current status and future prospects. Cancer Treatment Reviews, 31(7), 536-545.
6. Eisen, T. (2007). Adjuvant therapy in renal cell carcinoma: Where are we? European Urology Supplements, 6(7), 492-498.
7. Escudier, B., Eisen, T., Stadler, W.M., Szczlik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear cell renal cell carcinoma. New England Journal of Medicine, 356(2), 125-134.
8. Escudier, B., Koralewski, P., Pluzanska, A., Ravaud, S., Bracarda, C., Szcyylik, C., et al. (2007). A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-alfa 2a vs placebo/interferon-alfa 2a as first-line therapy in metastatic renal cell carcinoma [Abstract 3]. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings, Part 1, 25(18S, June 20 Suppl.).
9. Figlin, R.A., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Négrier, X., et al. (2008). Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma [Abstract 5024]. Retrieved November 10, 2009, from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detailview&confID=55&abstractID=32895
10. Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., Bearman, S.I., Roy, V., McGrath, P.C., et al. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine, 345(23), 1655-1659.
11. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. New England Journal of Medicine, 356(22), 2271-2281.
12. Klatte, T., de Martino, M., Shuch, B., LaRochelle, J., Kabbbinavar, F.F., Belldegrun, A.S., et al. (2008). Long-term outcome of interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma [Abstract 5119]. Retrieved November 10, 2009, from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detailview&confID=55&abstractID=30901
13. Kroog, G.S., & Motzer, R.J. (2008). Systemic therapy for metastatic renal cell carcinoma. Urologic Clinics of North America, 35(4), 687-701.
14. McDermott, D.F., Regan, M.M., Clark, J.I., Flaherty, L.E., Weiss, G.R., Logan, T.F., et al. (2005). Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 23(1), 133-141.
15. Mickisch, G.H., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001). Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: A randomised trial. Lancet, 358(9286), 966-970.
16. Moldawer, N.P., & Figlin, R. (2008). Renal cell carcinoma: The translation of molecular biology into new treatments, new patient outcomes, and nursing implications. Oncology Nursing Forum, 35(4), 699-708.
17. Motzer, R.J., & Basch, E. (2007). Targeted drugs for metastatic renal cell carcinoma. Lancet, 370(9605), 449-456.
18. National Cancer Institute. (2009). Dictionary of cancer terms: Glossary of statistical terms. Retrieved November 2, 2009, from http://www.cancer.gov/dictionary/?CdrlD=618612
19. National Comprehensive Cancer Network. (2009). NCCN Clinical Practice Guidelines in Oncology™. Kidney cancer [v.2.09]. Retrieved July 31, 2009, from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
20. ® [Prescribing information]. East Hanover, New Jersey: Author.
21. ® [Prescribing information]. Emeryville, CA: Author.
22. Pantuck, A.J., Zisman, A., & Belldegrun, A.S. (2001). The changing natural history of renal cell carcinoma. Journal of Urology, 166(5), 1611-1623.
23. ® [prescribing information]. New York: Author.
24. Rini, B.I., & Campbell, S.C. (2007). The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. Journal of Urology, 177(6), 1978-1984.
25. Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S., et al. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. Journal of Clinical Oncology, 26(33), 5422-5428.
26. Schrader, A.J., & Hofmann, R. (2008). Metastatic renal cell carcinoma: Recent advances and current therapeutic options. Anticancer Drugs, 19(3), 235-245.
27. Wang, Y. (2007). Ticilimumab. Drugs of the Future, 32(4), 337.
28. Weber, J. (2007). Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events. Oncologist, 12(7), 864-872.
29. Wood, L.S., & Manchen, B. (2007). Sorafenib: A promising new targeted therapy for renal cell carcinoma. Clinical Journal of Oncology Nursing, 11(5), 649-656.